(Q87129917)
Statements
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes (English)
J Dziuba
P Alperin
J Racketa
U Iloeje
D Goswami
E Hardy
I Perlstein
H L Grossman